Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0JDNBK
ADC Name	huAb3v2.5-ZZ
Synonyms	huAb3v2.5 ZZ; huAb3v2.5ZZ Click to Show/Hide
Organization	AbbVie, Inc.
Drug Status	Investigative
Indication	In total 1 Indication(s) Small cell lung cancer [ICD11:2C25] Investigative
Drug-to-Antibody Ratio	1.2
Structure
	3D MOL	2D MOL
Antibody Name	huAb3v2.5		Antibody Info
Antigen Name	CD276 antigen (CD276)		Antigen Info
Payload Name	Undisclosed
Linker Name	huAb3v2.5-ZZ linker
Combination Type	AbbVie's ZZ

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Effective Concentration (EC50)	1.1	nM	NCI-H1650 cells	Lung adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.10 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

References

Ref 1	Anti-b7-h3 antibodies and antibody drug conjugates; 2018-03-08.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.